Dexcom Inc. stock edges higher as Truist Securities reiterates Buy rating
Published on 09/17/2026 at 19:12 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Dexcom Inc. stock (ISIN US2521311074) ended regular Nasdaq trading at USD 87.34 on September 16, 2026, up 1.0 percent from the previous close and continuing a modest recovery in the continuous glucose monitoring specialist.
Analyst support underpins Dexcom valuation
Analyst backing remains a key pillar for Dexcom Inc. stock, with Truist Securities reaffirming a Buy recommendation and setting a price target of USD 93.00 in a recent research report, reinforcing a positive stance on the company’s medium-term prospects.MarketBeat According to data aggregated by MarketBeat, Dexcom currently carries a Moderate Buy consensus rating from analysts and an average price target of USD 88.71, leaving the shares trading slightly below the mean target.
Other research houses have also adjusted their views upward, with Royal Bank of Canada lifting its target from USD 85.00 to USD 90.00 and assigning an Outperform rating, while BTIG Research raised its target from USD 80.00 to USD 90.00 alongside a Buy recommendation.MarketBeat Argus has gone further, increasing its target from USD 86.00 to USD 96.00 while keeping a Buy rating, signaling confidence in Dexcom’s ability to grow earnings and cash flows.MarketBeat
Recent earnings show solid growth momentum
Dexcom’s latest reported quarterly figures underpin this positive analyst stance. In its most recent earnings release, the company reported quarterly revenue of USD 1.31 billion and adjusted earnings of USD 0.70 per share, with both metrics exceeding analyst expectations.MarketBeat While the exact year-on-year comparison is not specified in the latest summary, the beat versus consensus underscores Dexcom’s ability to deliver higher volumes and improved profitability in its continuous glucose monitoring franchise during the quarter.
The earnings surprise comes against a backdrop of rising institutional participation in the stock, with roughly 97.75 percent of outstanding shares held by institutional investors and hedge funds.MarketBeat For investors, that high ownership share can mean both strong support from professional capital and greater sensitivity to shifts in earnings expectations or sector sentiment.
Insider activity and valuation context
Inside the company, several recent share sales by executives and directors have drawn attention but have not altered the broadly favorable analyst stance. Director Nicholas Augustinos disclosed sales totaling 6,539 shares of Dexcom stock, while another insider, Michael Jon Brown, reported a separate sale of 1,700 shares.MarketBeatMarketBeat These transactions amount to a small fraction of Dexcom’s equity base and occur in a context where the company’s market capitalization stands near USD 29 billion as of mid September 2026.Morningstar
From a valuation perspective, the current price of USD 87.34 sits modestly below the average analyst target of USD 88.71 and also under the more optimistic Argus target of USD 96.00, suggesting potential upside in the eyes of many covering analysts.MarketBeat However, the same consensus also embeds expectations for continued double-digit revenue growth and margin resilience, so any slowdown in unit growth or pricing in Dexcom’s continuous glucose monitoring systems could weigh on the shares.
Stock trades near recent highs on Nasdaq
On September 16, 2026, Dexcom Inc. stock traded in a range between an intraday low around USD 86.45 and a high near USD 88.10 before closing at USD 87.34 on Nasdaq, with roughly 3.54 million shares changing hands in regular trading.ad-hoc-newsMarketBeat As of September 17, 2026, indicative real time data from a Cboe BZX feed show Dexcom shares quoted near USD 87.58, reflecting a gain of 0.27 percent over the latest comparison level and a 3.90 percent increase over the past five trading days.MarketScreener
Dexcom is listed on Nasdaq under the ticker DXCM and operates in the medical devices segment of the healthcare sector, focusing on continuous glucose monitoring systems used by people living with diabetes. For investors, the interplay between strong recent earnings, high institutional ownership, supportive analyst targets and ongoing insider share sales forms the current narrative around Dexcom Inc. stock as of mid September 2026.
Dexcom Inc. stock profile
- Company: Dexcom Inc.
- ISIN: US2521311074
- Ticker: DXCM
- Trading venue: Nasdaq
- Price (as of September 16, 2026): 87.34 USD
- Market capitalization: 29,000,000,000 USD (as of September 17, 2026)
- Sector / Industry: Healthcare / Medical Devices
- Index membership: S&P 500
